IRVINE, Calif.--(BUSINESS WIRE)--Nihon Kohden, a global leader in medical device innovation for high-precision patient monitoring and diagnostics, today announced the acquisition of a 71.4% stake in NeuroAdvanced Corp., the parent company of Ad-Tech Medical Instrument Corporation (Ad-Tech), a trusted provider of specialized electrodes for epilepsy treatment and neurodiagnostic procedures.

加利福尼亚州欧文市（商业新闻短讯）--高精度患者监测和诊断医疗设备创新的全球领导者日本科登（NihonKohden）今天宣布收购NeuroAdvanced Corp.71.4%的股份，NeuroAdvanced Corp.是Ad Tech medical Instrument Corporation（Ad Tech）的母公司，Ad Tech是癫痫治疗和神经诊断程序专用电极的可靠供应商。

The move further solidifies Nihon Kohden's position as an industry leader by combining its established expertise in EEG systems with Ad-Tech’s specialized intracranial electrodes—strengthening the company’s ability to address complex neurological conditions, including drug-resistant epilepsy..

此举进一步巩固了日本Kohden作为行业领导者的地位，将其在脑电图系统方面的专业知识与Ad Tech的专用颅内电极相结合，增强了该公司应对复杂神经系统疾病（包括耐药性癫痫）的能力。

By combining its six decades of deep-rooted expertise in neurology diagnostics with Ad-Tech’s best-in-class consumables, Nihon Kohden is primed to deliver even more impactful and integrated care. With both companies already present in a majority of the top 50 U.S. hospitals, the acquisition creates added synergy and ease of adoption for clinicians and hospital systems nationwide..

通过将其60年来在神经病学诊断方面根深蒂固的专业知识与Ad Tech一流的消耗品相结合，日本Kohden有望提供更具影响力和综合性的护理。由于两家公司已经在美国50家顶级医院中占据多数，此次收购为全国的临床医生和医院系统创造了更多的协同作用和易于采用的优势。

“This acquisition represents a pivotal step in advancing critical solutions for epilepsy care,” said Roy Sakai, President of Nihon Kohden America. “By uniting our strengths, we’re enhancing our ability to provide end-to-end support for epilepsy—from accurate diagnosis to advanced interventions.”

日本Kohden America总裁罗伊·酒井（RoySakai）表示：“此次收购是推进癫痫治疗关键解决方案的关键一步。”。“通过联合我们的力量，我们正在增强为癫痫提供端到端支持的能力，从准确的诊断到先进的干预措施。”

Ad-Tech’s electrode devices—used in long-term EEG monitoring, brain mapping, SEEG and brain stimulation—are instrumental in treating patients with intractable epilepsy and other neurological disorders. Since its founding in 1983, Ad-Tech has built a worldwide presence, with products approved in over 60 countries, including key markets in the U.S., Europe and Japan..

Ad-Tech的电极装置用于长期脑电图监测、脑图绘制、SEEG和脑刺激，有助于治疗顽固性癫痫和其他神经系统疾病患者。自1983年成立以来，Ad Tech在全球范围内建立了业务，产品已在60多个国家获得批准，包括美国、欧洲和日本的主要市场。

This strategic acquisition combines Nihon Kohden’s established expertise in EEG systems with Ad-Tech’s specialized electrodes, strengthening the company’s ability to support comprehensive epilepsy care. To realize Nihon Kohden’s Long-term Vision, BEACON 2030, the company aims to provide optimal care across more of the patient and care giver’s journey.

这项战略性收购将日本Kohden在脑电图系统方面的成熟专业知识与Ad Tech的专用电极相结合，增强了该公司支持全面癫痫治疗的能力。为了实现日本Kohden的长期愿景BEACON 2030，该公司旨在为更多患者和护理人员的旅程提供最佳护理。

This collaboration helps support these solutions for patients in acute neurocritical care situations, preserving function and enabling precision with intraoperative neuromonitoring (IONM) and enhancing usefulness of patient data using its analytics and digital health solutions (DHS)..

这种合作有助于为急性神经重症监护患者提供这些解决方案，通过术中神经监测（IONM）保留功能并实现精确性，并使用其分析和数字健康解决方案（DHS）增强患者数据的有用性。

ARCHIMED, the previous owner of Ad-Tech, will remain as a minority JV partner with Nihon Koden. Since acquiring Ad-Tech in 2020, ARCHIMED has contributed to strengthening Ad-Tech’s business foundation and sustainable growth by deep involvement in their management, including the appointment of Brian Smith as CEO.

Ad Tech的前所有者ARCHIMED将继续与日本Koden作为少数合资伙伴。自2020年收购Ad Tech以来，ARCHIMED通过深入参与其管理，包括任命Brian Smith为首席执行官，为加强Ad Tech的业务基础和可持续增长做出了贡献。

Nihon Koden and ARCHIMED will work together to drive Ad-Tech’s future global growth..

日本Koden和ARCHIMED将共同努力，推动广告技术未来的全球增长。

To learn more about Nihon Kohden’s innovative solutions and collaborative research dedicated to advancing epilepsy treatment, visit nihonkohden.com.

要了解更多关于日本科登致力于推进癫痫治疗的创新解决方案和合作研究的信息，请访问nihonkohden.com。

About Nihon Kohden

关于日本

Founded in Japan in 1951, Nihon Kohden is a leading manufacturer, developer and distributor of medical electronic equipment, with subsidiaries in the U.S., Europe, Asia and Latin America. The company's products are now used in more than 120 countries, and it is the largest supplier of electroencephalography products worldwide.

日本Kohden于1951年在日本成立，是医疗电子设备的领先制造商、开发商和分销商，在美国、欧洲、亚洲和拉丁美洲设有子公司。该公司的产品现已在120多个国家使用，是全球最大的脑电图产品供应商。

A pioneer in transformational healthcare technology, Nihon Kohden has envisioned, designed and produced revolutionary devices, such as pulse oximeters, arrhythmia analysis, low-invasive blood volume monitoring and wireless patient monitoring. To learn more, visit nihonkohden.com or us.nihonkohden.com, and follow Nihon Kohden on Facebook and LinkedIn..

作为变革性医疗保健技术的先驱，Nihon Kohden设想、设计并生产了革命性的设备，如脉搏血氧仪、心律失常分析、低侵入性血容量监测和无线患者监测。要了解更多信息，请访问nihonkohden.com或us.nihonkohden.com，并在Facebook和LinkedIn上关注Nihon Kohden。

About Ad-Tech

关于Ad Tech

Ad-Tech Medical is dedicated to helping surgeons, technicians and other caregivers deliver optimal outcomes for their patients. Physicians count on Ad-Tech's state-of-the-art electrodes for excellent design and engineering, world-class support and groundbreaking innovation. Ad-Tech devices are manufactured in the U.S.

Ad Tech Medical致力于帮助外科医生、技术人员和其他护理人员为患者提供最佳结果。医生们依靠Ad Tech最先进的电极进行出色的设计和工程、世界级的支持和开创性的创新。Ad-Tech设备在美国制造。

and used by healthcare providers worldwide to record, monitor and stimulate subsurface levels of the brain. To learn more, visit adtechmedical.com..

并被世界各地的医疗保健提供者用于记录，监测和刺激大脑的地下水平。要了解更多信息，请访问adtechmedical.com。

About ARCHIMED

关于ARCHIMED

With offices in Europe, North America and Asia, ARCHIMED is a leading investment firm focused exclusively on healthcare industries. Its mix of operational, medical, scientific and financial expertise allows ARCHIMED to serve as both a strategic and financial partner to healthcare businesses. Prioritized areas of focus include MedTech, Biopharma Products, Consumer Health, Healthcare IT, In Vitro Diagnostics, Life Science Tools & Biologic Services, and Pharma Services.

ARCHIMED在欧洲、北美和亚洲设有办事处，是一家专注于医疗保健行业的领先投资公司。其综合了运营、医疗、科学和财务方面的专业知识，使ARCHIMED成为医疗保健业务的战略和财务合作伙伴。优先关注的领域包括医疗技术、生物制药产品、消费者健康、医疗保健IT、体外诊断、生命科学工具和生物服务以及制药服务。

ARCHIMED helps partners internationalize, acquire, innovate and expand their products and services. ARCHIMED manages €8 billion across its various funds. Since inception, ARCHIMED has been a committed Impact investor, both directly and through its EURÊKA Foundation..

ARCHIMED帮助合作伙伴实现产品和服务的国际化、收购、创新和扩展。ARCHIMED管理着80亿欧元的各类基金。自成立以来，ARCHIMED直接或通过其EURÊKA基金会一直是一家致力于影响力的投资者。

Editor’s note:

编者按：

Discover how Nihon Kohden and Ad-Tech are revolutionizing neurological care by visiting booths #1939 and #1919 at the American Epilepsy Society (AES) Annual Meeting, from December 6-10, 2024, at the Los Angeles Convention Center.

2024年12月6日至10日，在洛杉矶会议中心举行的美国癫痫学会（AES）年会上，参观#1939和#1919展位，了解日本科登和Ad Tech如何彻底改变神经保健。